Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 66,8 M
EBIT 2016 4,47 M
Net income 2016 -9,49 M
Debt 2016 48,8 M
Yield 2016 -
Sales 2017 91,2 M
EBIT 2017 10,9 M
Net income 2017 -2,55 M
Debt 2017 72,1 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,13x
EV / Sales2017 4,75x
Capitalization 361 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
01/19 NASDAQ : TLGT Investor Alert: Investigation over Possible Wrongdoing at Teligent..
01/17 TELIGENT : Biotech Mergers and Acquisitions Could See Significant Rebound
01/16 TELIGENT : Biotech Mergers and Acquisitions Could See Significant Rebound
01/11 TELIGENT : Regulation FD Disclosure (form 8-K/A)
01/11 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Regulation FD Disclosure
01/11 TELIGENT, INC. : Regulation FD Disclosure (form 8-K)
01/10 TELIGENT, INC. : To Present At 35th Annual J.P. Morgan Healthcare Conference On ..
01/04 ROBBINS ARROYO LLP : Is Investigating the Officers and Directors of Teligent, In..
01/03 TELIGENT, INC. : Announces FDA Approval For Three Abbreviated New Drug Applicati..
2016 TELIGENT, INC. : Announces FDA Approval Of Clobetasol Propionate Lotion 0.05%
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%361
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results